Send Inquiry

Request To Call Back

Imfinzi 120mg/2.4ml

Name: Imfinzi 120mg/2.4ml
Brand: K. K. PHARMA SOLUTIONS

Get a Price/Quote

MOQ : 10 Units

Imfinzi 120mg/2.4ml Specification

Origin of Medicine
Imported/International

Dosage Form
Injection

Packaging Type
Vial

Salt Composition
Durvalumab 120mg in 2.4ml (50mg/ml)

Pacakaging (Quantity Per Box)
1 vial per box

Life Span
Check expiry on pack; usually 18-24 months from manufacture

Indication
Treatment of unresectable stage III NSCLC and extensive-stage SCLC

Brand Name
Imfinzi

Drug Type
Biological (Monoclonal Antibody)

Ingredients
Durvalumab

Physical Form
Liquid Solution

Function

Recommended For
Adults with unresectable stage III non-small cell lung cancer and extensive-stage small cell lung cancer, previously treated with chemoradiation or chemotherapy

Dosage
120 mg per vial

Dosage Guidelines
Administer as an intravenous infusion as directed by healthcare provider, typically every 2, 3, or 4 weeks

Suitable For
Adults only

Quantity
1 vial

Storage Instructions
Store at 2C to 8C, do not freeze

Prescription Required
Yes

Marketed By
AstraZeneca Pharma

Patient Assistance Program
Available in certain countries

Molecular Weight
~146 kDa

Adverse Effects
Immune-mediated reactions, fatigue, cough, pneumonitis, diarrhea, rash

ATC Code
L01XC28

Drug Interactions
May interact with immunosuppressive agents

Regulatory Approvals
US FDA, EMA, DCGI (India) approved

Route of Administration
Intravenous (IV) infusion

Container Type
Single-use vial

Caution
For use under medical supervision only

Concentration
50 mg/ml

Color
Clear to slightly opalescent, colorless to slightly yellow solution

About Imfinzi 120mg/2.4ml

Imfinzi 120mg Injection is an anticancer drug used to treat several cancers, including non-small cell lung cancer, biliary tract cancer, liver cancer, and endometrial cancer. It works by blocking the PD-L1 protein on cancer cells. This allows the immune system to recognize and attack these cells more effectively.

Imfinzi 120mg Injection is administered as an intravenous infusion, typically given in a hospital or a clinical setting. Make sure to attend all scheduled appointments and follow your doctors instructions. Maintaining a healthy lifestyle, including a balanced diet and regular exercise, can help optimize the treatment's effectiveness.

Common side effects include fatigue, cough, nausea, and loss of appetite. Some patients may experience diarrhea, skin rash, or shortness of breath. If you experience severe or persistent side effects, contact your doctor immediately. Staying hydrated and reporting side effects early can help manage them effectively.

While on Imfinzi 120mg Injection, avoid activities that can increase your risk of infection, such as contact with sick individuals or large crowds. The drug can cause immune-related side effects, such as inflammation of the lungs, liver, or intestines, so report any unusual symptoms promptly.

Mechanism of Action and Benefits

Imfinzi (Durvalumab) acts as a PD-L1 inhibitor, helping the immune system recognize and destroy cancer cells by preventing them from evading immune detection. For patients with certain types of lung cancer, Imfinzi can provide meaningful progression-free and overall survival benefits, especially after standard chemoradiotherapy has been completed.

Administration and Dosage Guidance

Imfinzi is administered as an intravenous infusion by qualified healthcare providers, generally every 2, 3, or 4 weeks, based on your doctor's instructions. Each vial contains 120mg Durvalumab in 2.4ml (50mg/ml). Administration must occur in a clinical setting to monitor for possible adverse reactions and ensure patient safety.

Storage, Packaging, and Handling

Imfinzi is supplied in single-use glass vials, each containing one dose. The solution should be stored in a refrigerator at 2C to 8C and not frozen. Each package contains one vial, and the product should only be used if the solution appears clear to slightly opalescent and colorless to slightly yellow. Check the expiry date before use.

FAQ's of Imfinzi 120mg/2.4ml:

Q: How is Imfinzi 120mg/2.4ml administered to patients?

A: Imfinzi is given as an intravenous (IV) infusion under the supervision of a healthcare provider. The infusion is typically administered every 2, 3, or 4 weeks, as directed by your oncologist, depending on your treatment plan and response.

Q: What are the main indications for using Imfinzi?

A: Imfinzi is recommended for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) and for those with extensive-stage small cell lung cancer (SCLC), particularly after prior chemoradiation or chemotherapy.

Q: When should Imfinzi treatment be considered for lung cancer patients?

A: Imfinzi is considered after completion of initial chemoradiation therapy in unresectable stage III NSCLC, or post-chemotherapy in extensive-stage SCLC. Your doctor will determine the precise timing based on your treatment progress.

Q: Where should Imfinzi vials be stored before administration?

A: Imfinzi vials must be stored at 2C to 8C (refrigerated) and protected from freezing. They should remain in their original packaging until ready for use, and the product must be checked for expiry and clarity before administration.

Q: What precautions are needed during Imfinzi treatment?

A: Imfinzi should be used strictly under medical supervision due to potential immune-mediated adverse effects, such as pneumonitis, diarrhea, fatigue, rash, and possible drug interactions with immunosuppressant agents. Immediate medical support is essential if severe reactions occur.

Q: How does Imfinzi benefit patients with lung cancer?

A: Imfinzi helps the immune system recognize and destroy cancer cells by blocking the PD-L1 protein, which can result in improved progression-free and overall survival in suitable lung cancer patients.

Q: Is patient assistance available for Imfinzi therapy?

A: Yes, AstraZeneca offers patient assistance programs for Imfinzi in certain countries to support eligible patients in accessing treatment. Ask your healthcare provider or local supplier for more details on availability and eligibility.

Tell us about your requirement